Participants should not have evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation); (to be eligible, prothrombin time/international normalized ratio [PT INR] should be < 1.4 for patients not on warfarin)
Evidence of bleeding diathesis or coagulopathy. Therapeutic anticoagulation is permitted, but patients must be on a stable dose.
Patients with evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation).
Known coagulopathy or bleeding diathesis; those on therapeutic anticoagulation or anti-platelet agent are permitted only after discussing with the study PI
(Bevacizumab-related exclusion) Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or clinically significant coagulopathy (in the absence of therapeutic anticoagulation); any history of significant bleeding or thrombosis should be discussed with the study principal investigators (PIs)
History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation); current or recent (within 10 days of study enrollment) use of anticoagulants that, in the opinion of the investigator, would place the subject at significant risk for bleeding; prophylactic use of anticoagulants is allowed
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nNo prior or current evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation).
Evidence of bleeding diathesis or clinically significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Participants should not have evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation).
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Serious bleeding diathesis or those who are on therapeutic anticoagulation
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
Evidence of bleeding diathesis or significant coagulopathy (in absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation) within 4 weeks of first study dose
Evidence of bleeding diathesis or clinically significant coagulopathy
Known bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
History of bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or clinically significant coagulopathy.
Evidence or history of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
History of tumor-related or other serious hemorrhage, bleeding diathesis, or underlying coagulopathy
No coagulopathy or bleeding diathesis
Evidence of bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or coagulopathy
Clinical evidence of bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or coagulopathy
Patients who have clinical history of coagulopathy, bleeding diathesis or thrombosis within the past year
Evidence or history of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Inherited bleeding diathesis or coagulopathy with the risk of bleeding
REGORAFENIB EXCLUSION CRITERIA: Evidence or history of bleeding diathesis or coagulopathy
History of or genetic predisposition to a bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or coagulopathy
Patients who have clinical history of coagulopathy, bleeding diathesis or thrombosis within the past year
Evidence of clinically significant bleeding diathesis or underlying coagulopathy, non-healing wound
The subject has inherited bleeding diathesis or coagulopathy with the risk of bleeding
Evidence of bleeding diathesis, coagulopathy as documented by an elevated PT, PTT or bleeding time
Clinical evidence of bleeding diathesis or coagulopathy
History or evidence of inherited bleeding diathesis or coagulopathy with a risk of bleeding
Evidence or history of bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or coagulopathy (including clinically significant hemoptysis)
Evidence of active bleeding diathesis or coagulopathy\r\n* For the NSCLC expanded cohort only: history of “blood tinged” sputum allowed
Bleeding or evidence or history of clinically significant bleeding diathesis or coagulopathy within the last 3 months
Clinically significant bleeding diathesis or coagulopathy
History or evidence of inherited bleeding diathesis or coagulopathy with a risk of bleeding
Evidence or history of bleeding diathesis or coagulopathy
Patients with a known coagulopathy or bleeding diathesis or require the use of systemic anticoagulant medication are not eligible
Evidence of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Patients must not have a known bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
No significant bleeding within the past 6 months; no bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or coagulopathy.
Evidence of bleeding diathesis or coagulopathy
Patients are excluded if they have evidence of bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding
Evidence or history of bleeding diathesis or coagulopathy.
Evidence or history of bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or coagulopathy within the past 6 months
Evidence of bleeding diathesis or coagulopathy within 3 months
Patients with a history of hemoptysis, bleeding diathesis, known platelet disorder, or coagulopathy are not eligible
Evidence of bleeding diathesis or clinically significant coagulopathy
Evidence of prior or current coagulopathy or bleeding diathesis
Clinically-significant evidence of bleeding diathesis or coagulopathy as so judged by the treating physician
Evidence or history of bleeding diathesis or coagulopathy
Patients must have no evidence of bleeding diathesis or coagulopathy; patients must have no pathologic condition other than mesothelioma that carries a high risk of bleeding
Evidence or history of bleeding diathesis or coagulopathy
Pre-existing bleeding diathesis, coagulopathy or hemorrhage
The subject has inherited bleeding diathesis or coagulopathy with the risk of bleeding
Patients must have no known bleeding diathesis or coagulopathy that would make intratumoral injection or biopsy unsafe.
Evidence or history of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Evidence of bleeding diathesis or clinically significant coagulopathy
Evidence of bleeding diathesis or a clinically significant coagulopathy
Patients with an active, bleeding diathesis or significant coagulopathy
History of bleeding diathesis or coagulopathy. (Patients on stable anticoagulant therapy are eligible.)
Evidence of bleeding diathesis or significant coagulopathy
Evidence or history of bleeding diathesis or uncontrolled coagulopathy
Evidence or history of a bleeding diathesis or coagulopathy, including therapy-induced coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Concurrent use of anti-coagulant drugs (not including prophylactic doses), history of coagulopathy, or evidence of bleeding diathesis or coagulopathy
Presence of bleeding diathesis or coagulopathy
No known bleeding diathesis or coagulopathy
History of bleeding diathesis or coagulopathy
Coagulopathy or bleeding diathesis
Evidence of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy.
Evidence or history of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Evidence of clinically significant bleeding diathesis or coagulopathy
Active GI bleeding and any bleeding diathesis or coagulopathy that is not correctable by usual therapy or hemostatic agents
Evidence of clinically significant bleeding diathesis or underlying coagulopathy (e.g. INR > 1.5 without vitamin K antagonist therapy), non-healing wound
Patients must not have a bleeding diathesis, hereditary of acquired bleeding disorder or coagulopathy
History of bleeding diathesis or coagulopathy other than that due to anticoagulation therapy
Evidence or history of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy at the time of enrollment
History or evidence of inherited bleeding diathesis or coagulopathy with a risk of bleeding and active gastrointestinal bleeding
Evidence or history of bleeding diathesis or coagulopathy
History of tumor-related or other serious hemorrhage, bleeding diathesis, or underlying coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Any evidence of bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders
Evidence or history of bleeding diathesis or coagulopathy
Known bleeding diathesis or coagulopathy
Evidence or history of bleeding diathesis or coagulopathy
Known bleeding diathesis or coagulopathy
Patient must not have a known bleeding diathesis or coagulopathy
Patients with evidence of active bleeding or bleeding diathesis will be excluded (Note: patients aged > 17 years with excess of 2.5 mL of hemoptysis are not eligible)
Patients with an active, bleeding diathesis
Patients with a history of bleeding diathesis are ineligible
History of bleeding diathesis or clinically significant bleeding within 14 days prior to randomization.
History of hemolytic anemia or bleeding diathesis
Patients with an active, bleeding diathesis
Known hemorrhagic diathesis or active bleeding disorder
Subjects may not have a history of bleeding diathesis or abnormal sensitivity to ionizing radiation
Patients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumarin)
Recent or active bleeding diathesis or arterial vascular event within 4 weeks
Patients with an active bleeding diathesis
If they have had any active bleeding in the last =< 4 weeks or have an otherwise known bleeding diathesis
Requires therapeutic anticoagulation or has known active bleeding diathesis
Active uncontrolled bleeding or a known bleeding diathesis
Contraindication for ibrutinib use because of a bleeding diathesis.
Evidence of a bleeding diathesis.
History of bleeding diathesis
Active uncontrolled bleeding or a known bleeding diathesis
Any evidence of bleeding diathesis (patients on therapeutic warfarin or heparin will be excluded)
Evidence of active bleeding or bleeding diathesis
Known history of bleeding diathesis
Evidence or history of bleeding diathesis
Patients with an active bleeding diathesis
Patients with an active bleeding diathesis
Patient on anticoagulation or with bleeding diathesis due to risk of hematomas at injection site
Patients with evidence of bleeding diathesis are not eligible
For patients undergoing serial tumor biopsies, known bleeding diathesis or history of abnormal bleeding or require anti-coagulation therapy which cannot be interrupted for biopsy
Any active bleeding in the last =< 4 weeks or have an otherwise known bleeding diathesis
PHASE II DOSE EXPANSION IN RECURRENT GBM UNDERGOING RESECTION: Evidence of bleeding diathesis or use of anticoagulant medication or any medication that may increase the risk of bleeding that cannot be stopped prior to surgery
Evidence or history of bleeding diathesis
Must not have any evidence of bleeding diathesis or active gastrointestinal bleeding
Patients must not have had any active bleeding in the last =< 4 weeks or have an otherwise known bleeding diathesis
History of bleeding disorder or diathesis
Presence of bleeding diathesis
Evidence of active bleeding or bleeding diathesis
No active uncontrolled bleeding/bleeding diathesis
Active bleeding diathesis or history of major bleeding, central nervous system (CNS) bleeding, or significant hemoptysis within the past 6 months
Evidence of active bleeding or bleeding diathesis
Evidence of uncontrollable bleeding diathesis
Evidence of bleeding diathesis or use of anticoagulant medication or any medication that may increase the risk of bleeding that cannot be stopped prior to surgery
Evidence of active bleeding or bleeding diathesis
Patients with an active bleeding diathesis
Bleeding diathesis, not correctable by usual forms of therapy
Bleeding diathesis, not correctable by usual forms of therapy
Active uncontrolled bleeding or a known bleeding diathesis
Haemorrhagic diathesis (i.e. haemophilia)
If they have had any active bleeding in the last =< 4 weeks or have an otherwise known bleeding diathesis
Active uncontrolled bleeding or a known bleeding diathesis
Patients with an active, bleeding diathesis
Evidence of active bleeding or bleeding diathesis
Subjects with known bleeding diathesis will be excluded from the study.
Patients with history of bleeding diathesis are ineligible
Subjects with history of bleeding diathesis
Patients with evidence of active bleeding or bleeding diathesis will be excluded (patients with excess of 2.5 mL of hemoptysis are not eligible)
Evidence of bleeding diathesis
Patients with evidence of active bleeding diathesis
Patients with an active, bleeding diathesis
Patients with an active, bleeding diathesis
Patients with an active, bleeding diathesis
Patients with an active, bleeding diathesis
Known hemorrhagic diathesis or active bleeding disorder
Active bleeding diathesis or history of any major bleeding, central nervous system (CNS) bleeding, or significant hemoptysis within 6 months of enrollment
History of bleeding diathesis.
Known history of a bleeding diathesis.
Evidence of active bleeding or bleeding diathesis
Evidence of active bleeding or bleeding diathesis
Evidence of bleeding diathesis
History of congenital bleeding diathesis
Active bleeding diathesis
Patients with history of bleeding diathesis
History of hemolytic anemia or bleeding diathesis
In the opinion of the investigator, bleeding diathesis or anticoagulation therapy that would preclude intramuscular injections
Evidence of history of bleeding diathesis.
Active bleeding diathesis
Significant history of bleeding events or pre-existing bleeding diathesis =< 6 months of randomization (unless the source of bleeding has been resected)
Patients with active bleeding diathesis
Patients with evidence or history of any bleeding diathesis, irrespective of severity
Patients must not have any evidence of bleeding diathesis or active gastrointestinal bleeding
Patients with evidence of a bleeding diathesis
Evidence of active bleeding or bleeding diathesis
Any active uncontrolled bleeding or bleeding diathesis
Evidence of active bleeding or bleeding diathesis
History of bleeding diathesis
Patients must not have any evidence of bleeding diathesis or active gastrointestinal bleeding
Evidence of active bleeding or bleeding diathesis
History of bleeding diathesis or extensive bleeding requiring blood transfusion within 14 days of enrollment
Patient must not have evidence of active bleeding or bleeding diathesis
Evidence of active bleeding or bleeding diathesis
Patients with an active, bleeding diathesis
Evidence of active bleeding or bleeding diathesis
Significant history of bleeding events or pre-existing bleeding diathesis, within 6 months of randomization (unless the source of bleeding has been resected)
Evidence of active bleeding or bleeding diathesis
Evidence of active bleeding or bleeding diathesis
Evidence of active bleeding or bleeding diathesis
Evidence of active bleeding or bleeding diathesis
EXPANSION COHORT ONLY: Evidence of active bleeding or bleeding diathesis
Known bleeding diathesis
Patients must not have any evidence of bleeding diathesis
Patients taking anticoagulants or with a history of a bleeding diathesis
Evidence of active bleeding or bleeding diathesis
Evidence of active bleeding or bleeding diathesis; any medical condition requiring systemic anticoagulation (including anti-platelet agents)
Have evidence or history of any bleeding diathesis (including mild hemophilia), irrespective of severity.
Evidence of a bleeding diathesis that cannot be corrected with standard therapy or factor replacement
Evidence of active bleeding or bleeding diathesis.
Patients with an active, bleeding diathesis
Known bleeding diathesis or hemophilia
Known bleeding diathesis Known history of hereditary hemorrhagic telangiectasia (HHT).
Active, bleeding diathesis.
Known bleeding diathesis.
For patients undergoing serial tumor biopsies, known bleeding diathesis or history of abnormal bleeding or require anti-coagulation therapy.
No history of bleeding diathesis.
Patients with an active, bleeding diathesis
History of bleeding diathesis
Evidence of active bleeding or bleeding diathesis.
No bleeding diathesis
Patients must not have any evidence of bleeding diathesis or signs of active bleeding
History of bleeding diathesis
Known bleeding diathesis
Patients with evidence of a bleeding diathesis that cannot be corrected with standard therapy or factor replacement
Patients with an active, bleeding diathesis
Evidence of active bleeding or bleeding diathesis
Patients with an active, bleeding diathesis
Patients with an active, bleeding diathesis
Bleeding diathesis, resulting in symptomatic bleeding.
Evidence of active bleeding or bleeding diathesis
No known bleeding diathesis
Known bleeding or thrombotic diathesis
Bleeding diathesis or inability to hold anticoagulation for surgery
Has known bleeding diathesis that would be a safety risk;
Active bleeding diathesis
Non-correctable bleeding diathesis
Familial bleeding diathesis
Known bleeding diathesis
History of a bleeding diathesis or current anticoagulant therapy
Bleeding diathesis
active, bleeding diathesis;
Patients with or with a history of uncontrolled bleeding diathesis
No history of bleeding diathesis
Patient must not have evidence of active bleeding or bleeding diathesis
Known bleeding diathesis or history of abnormal bleeding, or any other known coagulation abnormalities that would contraindicate the tumor biopsy procedure.
Known bleeding diathesis or history of abnormal bleeding, or any other known coagulation abnormalities that would contraindicate the tumor biopsy procedure.